Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer

Category Primary study
JournalAnnals of Oncology
Year 2021
This article has no abstract
Epistemonikos ID: 260f6e4acf9fca698f7ce80a82767a226b64730c
First added on: Dec 20, 2022